Drugs / BI 1815368
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 16 trials | ||||||
| Phase 1 | NCT07693218 | Jul → Sep 2026 overdue | — | Boehringer Ingelheim | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06655220 | Nov → Dec 2024 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT06494774 | Aug → Nov 2024 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT05965583 | Aug → Oct 2023 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT05857878 | Jun 2023 → Jun 2024 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT05337592 | Jun → Oct 2022 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06962839 | Jun 2025 → Sep 2027 expected | macular retinal edema | Boehringer Ingelheim | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BI 1815368 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05857878 ↗ |
| Route | Oral | “following oral administration of single rising doses” NCT05337592 ↗ |